Navigation Links
PharmAthene CEO To Participate on Biosecurity Panel at the 2010 BIO International Conference
Date:5/4/2010

ANNAPOLIS, Md., May 4 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that the Company's Interim CEO, Eric I. Richman, will be participating on a special biosecurity panel presentation promoting the critical interrelationship between government, academia and industry in the development of medical countermeasures vital to our nation's biosecurity.

The panel presentation, entitled "Public Private Partnerships for State-of-the-Art Countermeasures" will be held at 4:00 pm EDT on Wednesday, May 5, 2010, as part of the inaugural 2010 Biosecurity Conference, co-located with the 2010 BIO International Conference, May 3-6, 2010, McCormick Place, Chicago, IL.  

Officials in the biodefense industry note that increasing our nation's capability to rapidly and effectively develop and produce new and better medical countermeasures might not simply prevent casualties, but reduce the likelihood of such an attack.  Panelists, which include senior government officials and leading industry representatives will assess the process for the creation of these countermeasures and analyze the successes and challenges in their development through case studies and discussion, with the goal of enhancing our biodefense readiness and strategic national arsenal.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. PharmAthene Appoints Mitchel Sayare, Ph.D. to the Companys Board of Directors
2. PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
3. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
4. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
5. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
6. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
7. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
8. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
9. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
10. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
11. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected ... of 7.3% during the forecast period of 2016 to 2021 dominated ... accounted for the largest share of immunohistochemistry (IHC) market, by end ... , , ... market spread across 225 pages, profiling 10 companies and supported with ...
(Date:11/30/2016)... /PRNewswire/ - Portage Biotech Inc. ("Portage" or "the Company") ... to announce the formation of EyGen, Ltd. a ... assets through proof of concept. EyGen,s lead asset ... Pharmaceuticals Limited and being developed for topical ophthalmic ... segment diseases. This agent has the potential to ...
(Date:11/30/2016)... BEIJING , Nov. 30, 2016 Novogene ... services and solutions with cutting edge next-generation sequencing (NGS) ... a USD $75 Million [515 Million RMB] B round ... Capital Management ( Shenzhen ) Co., Ltd. ... Innovation") and Shanghai Sigma Square Investment Center LP ("Sigma ...
(Date:11/30/2016)... Woburn, MA (PRWEB) , ... November 30, 2016 ... ... broadband light sources for advanced technology applications, introduces the 5th generation, ultra-bright, Laser-Driven ... the highly successful Laser-Driven Light Source (LDLS™) technology, the EQ-77 offers higher radiance ...
Breaking Biology Technology:
(Date:6/9/2016)... , June 9, 2016 ... deploy Teleste,s video security solution to ensure the safety of ... during the major tournament Teleste, an ... systems and services, announced today that its video security solution ... to back up public safety across the country. The ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):